mission - university of hong...

12

Upload: vandat

Post on 14-Feb-2019

214 views

Category:

Documents


0 download

TRANSCRIPT

Mission

Pharmacovigilance and hospital acquired infection control - International Summer School

was born from a desire of cooperation between an Italo- American excellence

consortium, involving the Sbarro Institute for Cancer Research and Molecular Medicine

(USA) and the Pharmacological Risk Unit Medigenia (IT).

Chief of the initiative is prof. Antonio Giordano, head of the US Research Institute, a

world-renowned scientist and recently awarded of the ‘Grand Hippocrate’

Prize.

The Summer School was founded with the goal of providing an advanced scientific

training, which is essential to enable the participants to succeed and compete effectively

in healthy fields.

Program

The program promotes intercultural and professional dialogue approach and the

fulfillment of individual potential active in the context of a multidisciplinary dimension.

The Summer School will be held at the Sbarro Institute for Cancer Research and

Molecular, Philadelphia (USA).

It is divided into three days full time, 5 to 7 August 2013, during which will be

discussed the aspects that concern pharmacovigilance and its implications in Good

Clinical Practice, as well as the increasingly topical. and thorny problem of hospital

infections.

Expectation

The educational cut given by the scientific committee encourages advanced research

‘forma mentis’, thus providing not only what is purely notional, but a top class approach

centered on patient care as a unique individual. The young participants will acquire,

through the simulations of clinical cases and ex-cathedra lectures, an increasing ability,

decision-making autonomy and self- assertion in each own scientific reality.

Official language will be English.

Applications and fees

Admission decisions to the School are based on the totality of available information

about each applicant, and a careful evaluation of the candidate’s past accomplishments

and future promise. We have no mechanical shortcuts or substitutes for careful

consideration of each applicant.

The maximum number of participants is 25.

Candidates will be selected among the students enrolled in the last academic year of the

Faculty of Medicine and Surgery, Biology/Biotechnology and Pharmacy, specializing/ed

in medical areas as well as physicians, biologist and pharmacists graduated no more

than 5 years coming from EU Countries.

The cost of participation in the 'Pharmacovigilance and hospital acquired infection

control- Summer School' is 1,500€ and includes the training material, the use of the

library and ISCTE service facilities, certificate of attendance (with EBM credits) coffee

breaks, lunch catering, the Gala Dinner and Philadelphia’s city tour.

It's possible to join a full package, which includes the travel and accommodation full

board in Philadelphia (total cost 2,500€).

Participants may also apply for Summer School scholarship (750€ each one) fully

filling the Application Form.

Applications will be accurately sized up and within 5 day from transmission every

participant will receive a notification about acceptance or not.

To make effective the application after acceptance, the participant must pay the fee

using the following bank details:

Infostruttura onlus, via della Stanga 18, Gradisca d’Isonzo (Go), Italy

Swift /BIC code: UNCRITM1M27

Iban code: IT 84 I 02008 59550 000 100829680

ABI: 02008

CAB: 59550

Account number: 100829680

Reason of payment: Summer School

Should you need any further information or assistance please contact [email protected].

Thanks to the generous support of

Program

5 August 2013

8.30-9.00 am Registration

9.00-9.30 am Prof. Antonio Giordano

Director of Sbarro Institute for Cancer Research and Molecular Medicine

Greetings from the President to incoming students: ’our objective is not to train students, but for them to

train themselve’.

9.30-10.00 am Dr. Silvia Ussai

Director of Pharmaceutical Risk Unit ‘Medigenia’

Epidemiology of Adverse Drug Reaction (ADR): reasons behind underestimation and clinical relevance.

11.00-11.30 am Prof. Giuseppe Russo

Director of the Cancer Systems Biology and eHEALTH Programs, Sbarro Institute for Cancer Research and

Molecular Medicine, Temple University

Molecular biology in moving towards a personalized medicine.

10.00-11.00 am Dr. Silvia Ussai

Director of Pharmaceutical Risk Unit ‘Medigenia’

Skin lesions radiation- induced: the role of Water-Jel

11.30-12.00 am Coffee Break

12.00 am-12.30 pm Eng. Riccardo Petelin

Risk Manager and CEO Medigenia srl

Medigenia: a free health service that prevents ADRs using the social security number .

12.30 am-1.00 pm Dr. Fatima Morale Marin

Medical Science Researcher, University of Granada, Spain

Collaboration between Pharma Company and University

1.00-2.00 pm Lunch

2.00-3.00 pm Dr. Silvia Ussai

Director of Pharmaceutical Risk Unit ‘Medigenia’

Clinical cases simulation

With the contribution of

3.0-3.30 pm Prof. Eva Surmacz

Director, Obesity and Cancer, Sbarro Institute for Cancer Research and Molecular Medicine, Temple

University

Cardiovascular pharmocovigilance in Diabetes Research part 1

3.30-5.00 pm Discussion

8.00 pm Tour of the city

6 August 2013

9.30-10.30 am Eng. Riccardo Petelin

Risk Manager and CEO Medigenia srl

New tools to classify pharmacological risk.

10.30-11.00 am Prof. Marcella Macaluso

Director of Epigenetics and Genetics, Sbarro Institute for Cancer Research and Molecular Medicine, Temple

University

Oncology and epigenetics: an approach towards pharmacovigilance

11.00-11.30 Coffee break

11.30-12.00 am Dr. Silvia Ussai

Director of Pharmaceutical Risk Unit ‘Medigenia’

Over The Couter and alternative medicine surveillance.

12.00 am-1.00 pm Eng. Riccardo Petelin

Risk Manager and CEO Medigenia srl

Avoiding ADRs to make cheaper health insurance?

1.00-2.00 pm

Lunch

2.00-3.00 pm Dr. Silvia Boffo

Lead Scientist, CRO Aviano, Italy

Drug design and testing in animal models

3.00-4.00 pm Dr. Fatima Morales Marin

Medical Researcher, University of Granada, Spain

Oncology: pharmacovigilance in clinical practice.

4.00-5.00 pm Speakers Round Table

8.00 pm Gala dinner

7 August 2013

9.30-10.00 am Dr. Silvia Ussai

Director of Pharmaceutical Risk Unit ‘Medigenia’

Hospital acquired infections: incidence, prevalence, morbidity, mortality.

10.00-10.30 am Prof. Giuseppe Russo

Director of the Cancer Systems Biology and eHEALTH Programs, Temple University

Antimicrobial resistance: molecular mechanisms and recent study results.

10.30-11.00 am Dr. Fatima Morales Marin

Researcher, University of Granada, Spain

Pharmacovigilance in Europe: the Spain model

11.00-11.30 Coffee break

11.30-12.00 am Prof. Marcella Macaluso

Director of Epigenetics and Genetics, Sbarro Institute for Cancer Research and Molecular Medicine, Temple

University

Nutrigenomics and pharmacovigilance: state of art

12.00 am-12.30 pm Prof. Eva Surmacz

Director, Obesity and Cancer, Sbarro Institute for Cancer Research and Molecular Medicine, Temple

University

Cardiovascular pharmocovigilance in Diabetes Research part 2

12.30 am-1.00 pm Dr. Silvia Boffo

Lead Scientist, CRO Aviano, Italy

Drug response prediction in polypharmacy

1.00-2.00 pm Lunch

2.00-3.00 pm Discussion and closing remarks

Application Form for Admission

Section A: Your Personal Details

Please enter your name exactly as it appears on your passport or other official document.

FAMILY NAME TITLE (Mr, Mrs, Ms, Miss, etc.)

FIRST NAME GENDER: MALE FEMALE

MIDDLE NAME(S) DATE OF BIRTH: day _ _ / month _ _ / year _ _ _ _

PREFERRED NAME

Section B: Contact Information

HOME ADDRESS CORRESPONDENCE ADDRESS (if different)

CITY: CITY:

POSTAL/ZIP CODE: POSTAL/ZIP CODE:

STATE: STATE

COUNTRY: COUNTRY:

TELEPHONE (if you give more than one, please indicate which is the primary contact number)

TYPE

(mobile/cell phone,

daytime, evening, etc)

COUNTRY CODE

(if outside USA)

AREA CODE NUMBER

EMAIL ADDRESS (if you give more than one, please indicate which is the primary address)

Section C: Nationality & Citizenship

COUNTRY OF BIRTH:

COUNTRY OF NATIONALITY/CITIZENSHIP

Please include all countries that you have nationality of and give an effective date if you have not been a

national of that country from birth. Please do not give an end date unless your nationality of that country

has ended. Please give the number, nationality and expiry date of the passport that you intend to use to

enter the USA.

COUNTRY FROM (dd/mm/yyyy) TO (dd/mm/yyyy) PASSPORT NUMBER

AND EXPIRY DATE

(dd/mm/yyyy)

COUNTRY OF RESIDENCE

Please give details for the past 6 years. This should be the country in which you are normally resident not the country in

which you are studying. Please do not give an end date unless you no longer reside in that country.

COUNTRY FROM (dd/mm/yyyy) TO (dd/mm/yyyy)

Section D: Curriculum Vitae et studiorum

I’ve attached CV

Yes No

Section E: Scholarship

Medigenia and SHRO offer scholarships to help young doctors and scientists participate in the Summer School.

Each scholarship has a value of EUR 750,00. In order to qualify to be considered for a scholarship, you must fulfil the

following criteria:

Apply for Summer School

Be aged less than 35 years old

Provide a letter of support from your Department Head

Please send Application Form and personal CV to infomedigenia.com.

You will receive a confirmation about acceptance in the Summer School and scholarship within 5 days.

Declaration Once you have completed this application form, please read the following statements carefully. By signing this application form you confirm your acceptance of these statements. If you do not sign this form, we cannot process your application. I confirm that the information I have provided on this application form is (to the best of my knowledge) true, accurate, current and complete; and I agree to notify the SHRO/Medigenia promptly if any information contained on this application form should change, in order to keep it true, accurate, current and complete. I confirm that all supporting work submitted as part of this application is entirely my own original work, except where clearly indicated otherwise, and does not include any plagiarised elements. SIGNATURE:

DATE:

SIGNED (PLEASE PRINT NAME):